Home Biosimilar Antibodies Immunology & Inflammation CD markers Pepinemab (Anti-SEMA4D / CD100)
For research use only. Not for use in humans.

Pepinemab (Anti-SEMA4D / CD100)

Synonyms: CD100， SEMA4D

Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD.

Pepinemab (Anti-SEMA4D / CD100)

Quality Control

Batch: A236101 Purity: 99% Protein concentration: 3.55mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD.

Product Details

CAS No.  2097151-87-4
Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05102721 ACTIVE_NOT_RECRUITING Drug: Avelumab and Pepinemab Metastatic Pancreatic Adenocarcinoma Vaccinex Inc. 2022-12-10 PHASE1; PHASE2
NCT05378464 SUSPENDED Drug: Trastuzumab|Drug: Pepinemab HER2-positive Breast Cancer H. Lee Moffitt Cancer Center and Research Institute 2022-05-31 PHASE1
NCT04815720 COMPLETED Drug: pepinemab + pembrolizumab Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Vaccinex Inc. 2021-08-09 PHASE1; PHASE2
NCT04381468 COMPLETED Drug: Pepinemab|Drug: Placebo Alzheimer Disease Vaccinex Inc. 2021-07-22 PHASE1; PHASE2
NCT03373188 COMPLETED Colon Carcinoma Metastatic in the Liver; Colorectal Adenocarcinoma; Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma; Stage I Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Colorectal Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer Emory University 2017-12-15 PHASE1
NCT03425461 TERMINATED Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7 Jonsson Comprehensive Cancer Center 2018-06-14 PHASE1

(data from https://clinicaltrials.gov, updated on 2025-05-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.